Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Novocure Ltd

Healthcare US NVCR

17.99USD
1.84(11.39%)

Last update at 2026-06-04T20:00:00Z

Day Range

16.2318.39
LowHigh

52 Week Range

10.8782.64
LowHigh

Fundamentals

  • Previous Close 16.15
  • Market Cap2457.84M
  • Volume2250397
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-195.60899M
  • Revenue TTM525.66M
  • Revenue Per Share TTM4.92
  • Gross Profit TTM 423.58M
  • Diluted EPS TTM-1.81

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -81.84600M -52.07500M 18.10M -8.82400M -45.94200M
Minority interest - - - - -
Net income -92.53400M -58.35100M 19.81M -7.23000M -63.55900M
Selling general administrative 132.75M 126.13M 107.44M 87.95M 73.46M
Selling and marketing expenses 173.66M 137.06M 118.02M 96.67M 77.66M
Gross profit 422.97M 420.15M 387.87M 262.71M 168.02M
Reconciled depreciation 10.62M 10.25M 9.15M 8.46M 9.01M
Ebit -100.14700M -54.58400M 21.25M -9.37400M -42.67800M
Ebitda -89.52300M -44.33300M 30.40M -0.91400M -33.67200M
Depreciation and amortization 10.62M 10.25M 9.15M 8.46M 9.01M
Non operating income net other - - - - -
Operating income -89.52300M -44.33300M 21.25M -0.91400M -33.67200M
Other operating expenses 627.36M 579.36M 463.96M 352.23M 281.74M
Interest expense 3.33M 3.44M 13.15M 13.72M 13.49M
Tax provision 10.69M 6.28M -1.70600M -1.59400M 17.62M
Interest income 10.96M 0.79M 1.79M 4.40M 2.65M
Net interest income 11.20M -3.71000M -14.94700M -7.47900M -11.87200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 10.69M 6.28M -1.70600M -1.59400M 17.62M
Total revenue 537.84M 535.03M 494.37M 351.32M 248.07M
Total operating expenses 512.50M 464.49M 357.46M 263.63M 201.69M
Cost of revenue 114.87M 114.88M 106.50M 88.61M 80.05M
Total other income expense net 7.68M -7.74200M -3.14900M -7.91000M -0.39800M
Discontinued operations - - - - -
Net income from continuing ops -92.53400M -58.35100M 19.81M -7.23000M -63.55900M
Net income applicable to common shares -92.53400M -58.35100M 19.81M -7.23000M -63.55900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1146.13M 1191.65M 1139.49M 1051.98M 479.45M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 8.53M 6.70M 0.81M 11.50M 0.00100M
Total liab 783.63M 750.48M 729.00M 575.46M 261.66M
Total stockholder equity 362.50M 441.17M 410.49M 476.53M 217.79M
Deferred long term liab - - - - -
Other current liab -16.22400M -18.02800M -17.76200M 42.20M -0.00100M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -985.50300M -778.46000M -685.92600M -631.07700M -650.88500M
Other liab - 7.36M 11.19M 17.65M 11.72M
Good will - - - - -
Other assets - 11.16M 12.09M 10.91M 4.90M
Cash 240.82M 115.33M 208.80M 234.67M 177.32M
Cash and equivalents - - - - -
Total current liabilities 179.12M 158.78M 142.60M 113.61M 86.31M
Current deferred revenue 16.22M 18.03M 17.76M 17.77M 11.77M
Net debt 355.42M 468.94M 366.41M 209.52M -13.75700M
Short term debt 84.72M 73.58M 70.00M - 37.61M
Short long term debt - - - - -
Short long term debt total 596.24M 584.27M 575.21M 444.20M 163.56M
Other stockholder equity 1353.47M 1222.06M 1099.59M 1111.43M 871.44M
Property plant equipment - 32.68M 53.88M 11.39M 34.60M
Total current assets 1034.41M 1111.53M 1073.53M 999.44M 439.95M
Long term investments - - - - -
Net tangible assets - 441.17M 410.49M 476.53M 217.79M
Short term investments 669.79M 854.10M 728.90M 607.90M 148.77M
Net receivables 77.11M 112.22M 110.59M 117.94M 88.06M
Long term debt 568.82M 565.51M 562.22M 429.90M 149.42M
Inventory 38.15M 29.38M 24.43M 27.42M 23.70M
Accounts payable 94.39M 85.20M 72.60M 53.65M 36.92M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -5.46900M -2.43300M -3.16900M -3.83200M -2.76700M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -778.46000M -685.92600M -631.07700M -650.88500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 14.02M 11.16M 12.09M 10.91M 4.90M
Deferred long term asset charges - - - - -
Non current assets total 111.72M 80.12M 65.97M 52.54M 39.50M
Capital lease obligations 27.42M 18.76M 13.00M 14.29M 14.14M
Long term debt total - 565.51M 562.22M 429.90M 149.49M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -139.95700M -120.66400M -457.87900M -41.18200M 1.22M
Change to liabilities 4.27M 27.78M 26.13M 9.88M 23.22M
Total cashflows from investing activities -139.95700M -144.83400M -472.84700M -51.66700M -5.49300M
Net borrowings -0.02800M -0.02600M 408.41M -0.03100M 49.07M
Total cash from financing activities 15.49M 25.70M 440.21M 61.68M 69.37M
Change to operating activities -0.66600M -6.46100M -0.70200M -3.56000M 8.55M
Net income -92.53400M -58.35100M 19.81M -7.23000M -63.55900M
Change in cash -93.77500M -36.56400M 66.76M 36.66M 62.04M
Begin period cash flow 209.61M 246.17M 179.42M 142.76M 80.72M
End period cash flow 115.83M 209.61M 246.17M 179.42M 142.76M
Total cash from operating activities 30.79M 82.76M 99.15M 26.62M -1.86500M
Issuance of capital stock 5.22M 4.55M 3.37M 2.47M 1.83M
Depreciation 10.62M 10.25M 9.15M 8.46M 9.01M
Other cashflows from investing activities - - - -41.18200M -3.79500M
Dividends paid - - - - -
Change to inventory -4.34200M 2.48M -2.93500M -1.15900M -0.52900M
Change to account receivables 2.55M 5.27M -30.35400M -36.49600M -4.15100M
Sale purchase of stock 15.52M 25.73M 31.80M 61.71M 20.30M
Other cashflows from financing activities 10.29M 21.18M 586.87M 59.24M 167.62M
Change to netincome 104.65M 101.79M 75.45M 51.90M 40.25M
Capital expenditures 21.36M 24.17M 14.97M 10.48M 6.71M
Change receivables 2.55M 5.27M -30.35400M -36.49600M -4.15100M
Cash flows other operating 7.11M 4.52M -1.36600M 3.45M -7.12300M
Exchange rate changes - - - - -
Cash and cash equivalents changes -93.67800M -36.37600M 66.51M 36.63M 62.01M
Change in working capital 11.80M 29.07M -8.52100M -24.33200M 11.41M
Stock based compensation 106.95M 94.90M 75.72M 52.42M 39.85M
Other non cash items -6.05300M 3.01M 3.26M -2.17500M 1.02M
Free cash flow 9.43M 58.59M 84.18M 16.14M -8.57600M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NVCR
Novocure Ltd		 1.84 11.39% 17.99 - 909.09 2.85 4.01 2.24 -6.418
ABT
Abbott Laboratories		 3.79 4.36% 90.78 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 6.21 2.11% 301.21 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 3.98 5.11% 81.93 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.16 2.43% 48.85 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Novocure Ltd

No. 4 The Forum, Saint Helier, Jersey, JE2 4UF

Key Executives

Name Title Year Born
Mr. William F. Doyle Exec. Chairman 1962
Mr. Asaf Danziger Pres, CEO & Director 1966
Ms. Ashley Cordova Chief Financial Officer 1980
Mr. Wilhelmus C. M. Groenhuysen Chief Operating Officer 1958
Mr. Pritesh Shah Chief Commercial Officer 1978
Prof. Yoram Palti M.D., Ph.D. Founder & CTO 1938
Mr. Uri Weinberg M.D., Ph.D. Chief Science Officer NA
Ms. Ingrid Goldberg VP of Investor Relations NA
Mr. Barak Ben Arye Gen. Counsel NA
Mr. William Patrick Burke Chief HR Officer 1955

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions